Last $1.64 USD
Change Today -0.06 / -3.53%
Volume 193.9K
CNDO On Other Exchanges
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

coronado biosciences inc (CNDO) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/13 - $10.20
52 Week Low
11/15/13 - $1.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

coronado biosciences inc (CNDO) Related Bloomberg News

View More Bloomberg News

coronado biosciences inc (CNDO) Related Businessweek News

No Related Businessweek News Found

coronado biosciences inc (CNDO) Details

Coronado Biosciences, Inc., a development stage biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company's principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, and type 1 diabetes; and CNDO-109, a biologic that activates the immune system’s natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. Coronado Biosciences, Inc. has strategic alliances and commercial agreements with Ovamed GmbH, Dr. Falk Pharma GmbH, Freie Universität Berlin, UCL Business PCL, and Progenitor Cell Therapy. The company was founded in 2006 and is based in Burlington, Massachusetts.

14 Employees
Last Reported Date: 03/14/14
Founded in 2006

coronado biosciences inc (CNDO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $980.0
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $540.8K
Senior Vice President of Biologics Operations
Total Annual Compensation: $250.3K
Compensation as of Fiscal Year 2013.

coronado biosciences inc (CNDO) Key Developments

Coronado Biosciences, Inc.(NasdaqCM:CNDO) dropped from Russell 2000 Index

Coronado Biosciences, Inc. will be removed from the Russell 2000 Index.

Coronado Biosciences, Inc.(NasdaqCM:CNDO) dropped from Russell 3000 Index

Coronado Biosciences, Inc. will be removed from the Russell 3000 Index.

Coronado Biosciences Reports Topline Results From Investigator Initiated Pilot Study of TSO in Adults With Autism Spectrum Disorder

Coronado Biosciences, Inc. announced the completion of pilot study of oral TSO (Trichuris suis ova or CNDO-201) for adults with Autism Spectrum Disorder (ASD). The study was a double-blind, randomized, placebo-controlled, cross-over study and enrolled 10 high functioning adult autism spectrum disorder patients who were able to give informed consent to participate in the study, and who had a history of allergies and/or a family history of immune-inflammatory illness. They were treated for 12 weeks with either TSO or placebo, followed by a 4-week washout phase and then 12 weeks of placebo or TSO. The TSO dosage used in the study was 2,500 ova once every two weeks. While none of the measures reached statistical significance, benefits with TSO treatment (over placebo) were observed in several subscales, including the Montefiore-Einstein Rigidity Scale (MERS), ABC Irritability, RBS-R Sameness, and RBS-R Restricted Behavior. TSO was well-tolerated; no patient discontinued due to an adverse event (or due to tolerability issues), and 9 of 10 patients completed the full 26 week treatment period.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNDO:US $1.64 USD -0.06

CNDO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CNDO.
View Industry Companies

Industry Analysis


Industry Average

Valuation CNDO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORONADO BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at